Patents Assigned to StemBios Technologies, Inc.
-
Patent number: 11492592Abstract: A method for treating a condition, comprising administering to a subject in need thereof a composition that contains somatic stem cells that are 2 to less than 6 micrometers in size and Lgr5+, wherein the condition is selected from the group consisting of neurodegenerative disorder, muscle-degenerative disease, cancer, metabolic disorder, autoimmune disorder, inflammatory disorder, heart disorder, circulatory disorder, a condition associated with aging, and damaged tissue.Type: GrantFiled: August 7, 2019Date of Patent: November 8, 2022Assignee: Stembios Technologies, Inc.Inventor: James Wang
-
Patent number: 10143710Abstract: Described herein is a method of treating a disorder, the method comprising: administering to a subject in need thereof a composition that contains a population of somatic stem cells that are 0.3-6.0 micrometers in size and CD9+, CD349+, CD133?, CD90?, CD34?, SSEA1+, SSEA4+, CD13+, or Stro1+, wherein the disorder is selected from the group consisting of a neurodegenerative disease, nervous system disorder, cancer, metabolic disorder, autoimmune disorder, inflammatory disorder, heart or circulatory disorder, blood disorder, muscular dystrophy, gastrointestinal disease, kidney disease, liver disease, lung disease, adrenal disorder, a condition resulting from an injury, a condition associated with aging, and virus infection.Type: GrantFiled: August 12, 2016Date of Patent: December 4, 2018Assignee: StemBios Technologies, Inc.Inventor: James Wang
-
Patent number: 9856452Abstract: Described is an isolated somatic stem cell that is 2 to less than 6 micrometer in size and Lgr5+. Methods of preparing and using the cell are also described.Type: GrantFiled: September 4, 2015Date of Patent: January 2, 2018Assignee: StemBios Technologies, Inc.Inventor: James Wang
-
Patent number: 9810684Abstract: A method of evaluating an action includes (1) obtaining a first stem-cell data related to a subject before performing the action, (2) performing the action on the subject, (3) obtaining a second stem-cell data related to the subject after performing the action, and (4) identifying the effect of the action on the subject based on the first stem-cell data and the second stem-cell data. The subject may be a human or an animal. The action may be taking a drug or taking a nutrient or dietary supplement, which may include fucoidan. Each of the first and second stem-cell data may include the count of a type or types of stem cells and/or the percentage of the type or types of stem cells and may be obtained by the same method including counting cells using a cell counter or cell counting device such as flow cytometer.Type: GrantFiled: December 19, 2013Date of Patent: November 7, 2017Assignee: StemBios Technologies, Inc.Inventors: James Wang, Steve K Chen, Mou-Shiung Lin, Yun Yen
-
Patent number: 9777259Abstract: A somatic stem cell that is CD10+, CXCR4+, and CD31+ and another somatic stem cell that is CD105+, CD44+, and nestin+. Also disclosed are both a method of preparing these stem cells and a method of using them to treat degenerative diseases, e.g., a muscle-degenerative disease. The invention further includes making and using liver cells derived from the somatic cell that is CD105+, CD44+, and nestin+.Type: GrantFiled: October 7, 2015Date of Patent: October 3, 2017Assignee: StemBios Technologies, Inc.Inventor: James Wang
-
Patent number: 9770473Abstract: Disclosed are methods of using blastomere-like stem cells to decrease a level of myeloid-derived suppressor cells (MDSCs). A method for decreasing a level of myeloid-derived suppressor cells (MDSCs) in a human subject, including: injectionally, orally or transdermally administering to the human subject an amount of human blastomere-like stem cells, autologous to the human subject, at 1×108 to 1×1011 cells each time once every two weeks, for example.Type: GrantFiled: October 4, 2013Date of Patent: September 26, 2017Assignee: StemBios Technologies, Inc.Inventors: James Wang, Yun Yen, Lufen Chang
-
Patent number: 9415073Abstract: Described herein is a method of generating muscle cells in a subject. The method includes isolating a population of somatic stem cells that are CD133? and 0.3-6.0 micrometers in size and administering to a subject in need thereof an effective amount of the somatic stem cells, whereby the somatic stem cells differentiate into muscle cells in the subject.Type: GrantFiled: June 16, 2015Date of Patent: August 16, 2016Assignee: Stembios Technologies, Inc.Inventor: James Wang
-
Patent number: 9155763Abstract: Described is an isolated somatic stem cell that is 2 to less than 6 micrometer in size and Lgr5+. Methods of preparing and using the cell are also described.Type: GrantFiled: December 5, 2013Date of Patent: October 13, 2015Assignee: StemBios Technologies, Inc.Inventor: James Wang
-
Patent number: 9072719Abstract: A method of treating brain tissue damage or a neurodegenerative disease in a subject by obtaining from a subject a bodily fluid sample containing a plurality of cells, incubating the sample with EDTA or heparin in a container until the sample is separated into an upper layer and a lower layer, collecting the upper layer, isolating from the upper layer a population of somatic stem cells that are 0.3-6.0 micrometers in size, and administering to a subject in need thereof an effective amount of the somatic stem cells.Type: GrantFiled: May 16, 2013Date of Patent: July 7, 2015Assignee: StemBios Technologies, Inc.Inventor: James Wang
-
Patent number: 8986679Abstract: A method of treating a cellular proliferative disorder in a subject by obtaining from a subject a bodily fluid sample containing a plurality of cells, incubating the sample with EDTA or heparin in a container until the sample is separated into an upper layer and a lower layer, collecting the upper layer, isolating from the upper layer a population of somatic stem cells that are 0.3-6.0 micrometers in size, differentiating the somatic stem cells to dendritic cells in a medium containing GCSF, SCF, EGF, PDGF, bFGF, and IL-3, purifying the dendritic cells, contacting the dendritic cells thus purified with a cancer antigen, and administrating an effective amount of the dendritic cells presenting the cancer antigen to a subject in need thereof.Type: GrantFiled: May 16, 2013Date of Patent: March 24, 2015Assignee: Stembios Technologies, Inc.Inventor: James Wang
-
Publication number: 20140178886Abstract: A method of evaluating an action includes (1) obtaining a first stem-cell data related to a subject before performing the action, (2) performing the action on the subject, (3) obtaining a second stem-cell data related to the subject after performing the action, and (4) identifying the effect of the action on the subject based on the first stem-cell data and the second stem-cell data. The subject may be a human or an animal. The action may be taking a drug or taking a nutrient or dietary supplement, which may include fucoidan. Each of the first and second stem-cell data may include the count of a type or types of stem cells and/or the percentage of the type or types of stem cells and may be obtained by the same method including counting cells using a cell counter or cell counting device such as flow cytometer.Type: ApplicationFiled: December 19, 2013Publication date: June 26, 2014Applicant: STEMBIOS TECHNOLOGIES, INC.Inventors: James Wang, Steve K. Chen, Mou-Shiung Lin, Yun Yen
-
Publication number: 20140161774Abstract: Described is an isolated somatic stem cell that is 2 to less than 6 micrometer in size and Lgr5+. Methods of preparing and using the cell are also described.Type: ApplicationFiled: December 5, 2013Publication date: June 12, 2014Applicant: StemBios Technologies, Inc.Inventor: James Wang
-
Patent number: 8679474Abstract: A method of treating a cellular proliferative disorder with cancer antigen-activated dendritic cells that are derived from a population of somatic stem cells. Also disclosed are methods of treating tissue damages and degenerative diseases with a population of somatic stem cells.Type: GrantFiled: February 6, 2012Date of Patent: March 25, 2014Assignee: StemBios Technologies, Inc.Inventor: James Wang
-
Publication number: 20140030237Abstract: Disclosed are methods of using blastomere-like stem cells to treat a number of immunodeficiency disorders.Type: ApplicationFiled: October 4, 2013Publication date: January 30, 2014Applicant: StemBios Technologies, Inc.Inventors: James Wang, Yun Yen, Lufen Chang
-
Patent number: 8623642Abstract: A population of somatic stem cells and a method of preparing same. Also disclosed are two subpopulations thereof and their various uses.Type: GrantFiled: August 4, 2011Date of Patent: January 7, 2014Assignee: StemBios Technologies, Inc.Inventor: James Wang
-
Publication number: 20130236485Abstract: A method of treating a cellular proliferative disorder in a subject by obtaining from a subject a bodily fluid sample containing a plurality of cells, incubating the sample with EDTA or heparin in a container until the sample is separated into an upper layer and a lower layer, collecting the upper layer, isolating from the upper layer a population of somatic stem cells that are 0.3-6.0 micrometers in size, differentiating the somatic stem cells to dendritic cells in a medium containing GCSF, SCF, EGF, PDGF, bFGF, and IL-3, purifying the dendritic cells, contacting the dendritic cells thus purified with a cancer antigen, and administrating an effective amount of the dendritic cells presenting the cancer antigen to a subject in need thereof.Type: ApplicationFiled: May 16, 2013Publication date: September 12, 2013Applicant: StemBios Technologies, Inc.Inventor: James Wang
-
Publication number: 20130236435Abstract: A method of treating brain tissue damage or a neurodegenerative disease in a subject by obtaining from a subject a bodily fluid sample containing a plurality of cells, incubating the sample with EDTA or heparin in a container until the sample is separated into an upper layer and a lower layer, collecting the upper layer, isolating from the upper layer a population of somatic stem cells that are 0.3-6.0 micrometers in size, and administering to a subject in need thereof an effective amount of the somatic stem cells.Type: ApplicationFiled: May 16, 2013Publication date: September 12, 2013Applicant: StemBios Technologies, Inc.Inventor: James Wang
-
Publication number: 20130095077Abstract: A somatic stem cell that is CD10+, CXCR4+, and CD31+ and another somatic stem cell that is CD 105+, CD44+, and nestin+. Also disclosed are both a method of preparing these stem cells and a method of using them to treat degenerative diseases, e.g., a muscle-degenerative disease. The invention further includes making and using liver cells derived from the somatic cell that is CD105+, CD44+, and nestin+.Type: ApplicationFiled: September 28, 2012Publication date: April 18, 2013Applicant: StemBios Technologies, Inc.Inventor: James Wang
-
Patent number: 8394630Abstract: Disclosed are novel stem cells of non-embryonic origins and the uses thereof.Type: GrantFiled: January 13, 2010Date of Patent: March 12, 2013Assignee: StemBios Technologies, Inc.Inventors: James Wang, Yun Yen
-
Publication number: 20120177670Abstract: A method of treating a cellular proliferative disorder with cancer antigen-activated dendritic cells that are derived from a population of somatic stem cells. Also disclosed are methods of treating tissue damages and degenerative diseases with a population of somatic stem cells.Type: ApplicationFiled: February 6, 2012Publication date: July 12, 2012Applicant: StemBios Technologies, Inc.Inventor: James Wang